The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis

被引:33
作者
Aladul, Mohammed I. [1 ,2 ]
Fitzpatrick, Raymond W. [1 ]
Chapman, Stephen R. [1 ]
机构
[1] Keele Univ, Sch Pharm, Hornbeam Bldg, Newcastle Under Lyme ST5 5BG, Staffs, England
[2] Univ Mosul, Sch Pharm, Mosul, Nineveh, Iraq
关键词
Budget impact analysis; Biosimilar; Rheumatology; Gastroenterology; ETANERCEPT BIOSIMILARS; INFLIXIMAB; ARTHRITIS; DISEASE; CT-P13;
D O I
10.1016/j.sapharm.2018.05.009
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The approval of new biosimilars of infliximab, etanercept and adalimumab by the European Medicines Agency is expected to produce further cost savings to the healthcare system budget. Objectives: This study aimed to estimate the budget impact of the introduction of new biosimilars Flixabi (R), Erelzi (R), Solymbic (R), Amgevita (R) and Imraldi (R) in rheumatology and gastroenterology specialities in the UK. Methods: A published budget impact model was adapted to estimate the expected cost savings following the entry of new biosimilars Flixabi (R), Erelzi (R), Solymbic (R), Amgevita (R) and Imraldi (R) in the UK over three-year time horizon. This model was based on retrospective market shares of biologics used in rheumatology and gastroenterology which were derived from DEFINE Software and healthcare professional perspectives. Results: The model predicted that infliximab and etanercept biosimilars would replace their corresponding reference agents by 2020. Adalimumab biosimilars were predicted to achieve 19% of the rheumatology and gastroenterology market by 2020. Without the introduction of further biosimilars, the model predicted a reduction in expenditure of pound 44 million on biologics over the next three years. With the entry of Flixabi (R), Erelzi (R), Solymbic (R), Amgevita (R) and Imraldi (R) the model estimates cumulative savings of 285 pound million by 2020. Conclusions: The introduction of new infliximab, etanercept and adalimumab biosimilars will be associated with considerable cost savings and have a substantial favourable impact on the UK NHS budget. The number of biosimilars and time of entry of is critical to create competition which will result in maximum cost savings.
引用
收藏
页码:310 / 317
页数:8
相关论文
共 46 条
[1]   Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK [J].
Aladul, Mohammed I. ;
Fitzpatrick, Raymond W. ;
Chapman, Stephen R. .
BIODRUGS, 2017, 31 (06) :533-544
[2]  
[Anonymous], 2016, TNF ALPH INH ANK SPO
[3]  
[Anonymous], 2017, BRIT SOC RHEUMATOLOG
[4]  
Barber S, 2016, NATL ARTHRITIS WEEK
[5]   Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings? [J].
Beck, M. ;
Michel, B. ;
Rybarczyk-Vigouret, M-C ;
Sordet, C. ;
Sibilia, J. ;
Velten, M. .
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2017, 24 (02) :85-90
[6]  
British Society of Gastroenterology, 2016, BSG GUID US BIOS INF
[7]   Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries [J].
Brodszky, Valentin ;
Baji, Petra ;
Balogh, Orsolya ;
Pentek, Marta .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 :S65-S71
[8]   Has cost inhibited the uptake of more potent statins in England? [J].
Chapman, Stephen R. ;
Fitzpatrick, Raymond W. ;
Aladul, Mohammed I. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (08) :984-991
[9]   Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey [J].
Chapman, Stephen R. ;
Fitzpatrick, Raymond W. ;
Aladul, Mohammed I. .
BMJ OPEN, 2017, 7 (06)
[10]  
DECOCK D, 2017, ARTHRITIS RHEUM S10, V69